Last reviewed · How we verify
NCT07434869
Plasma and Radiologic Biomarkers of Response to ECP in Lung Transplant Recipients With CLAD
trial in Lung Transplant Failure and Rejection in 25 participants. Not yet recruiting.
28 February 2030
Quick facts
| Lead sponsor | Brian Keller |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 25 |
| Start date | 1 March 2026 |
| Primary completion | 28 February 2030 |
| Estimated completion | 28 February 2030 |
| Sites | 3 locations across United States |
Conditions studied
- Lung Transplant Failure and Rejection — all drugs for Lung Transplant Failure and Rejection →
- CLAD, Bronchiolitis Obliterans — all drugs for CLAD, Bronchiolitis Obliterans →
- Extracorporeal Photopheresis — all drugs for Extracorporeal Photopheresis →
Sponsor
Brian Keller
Who can join
7 and older, any sex, with Lung Transplant Failure and Rejection or CLAD, Bronchiolitis Obliterans. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is for people who have had a lung transplant and developed a condition called chronic lung allograft dysfunction (CLAD), which is a type of chronic rejection. Doctors often treat CLAD with a procedure called extracorporeal photopheresis (ECP), but it can take up to six months to know if the treatment is working. The goal of the study is to find early signs (biomarkers) that show whether ECP is helping, so patients can get the right care sooner. For participants in the study, small blood samples will be collected at three points during ECP treatment and, for some participants, two MRI scans of the lungs will be performed-one before starting ECP and one after finishing treatment. The MRI uses a safe contrast dye to help us see changes in lung blood flow and tissue. Investigators will also look at certain immune cells in the blood. This is not a study of a new drug or treatment-participants will receive the same ECP therapy their doctor already recommended. The study will help researchers understand how ECP works and identify markers that predict who benefits most. There is no direct benefit to participants, but participation may help improve care for future lung transplant patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07434869
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Transplant Failure and Rejection
Currently open trials in the same condition.
- NCT05050955 — AlloSure Lung Assessment and Metagenomics Outcomes Study · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07434869 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Brian Keller
- Last refreshed: 27 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07434869.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing